Vis enkel innførsel

dc.contributor.authorBjorkli, Christiana
dc.contributor.authorSandvig, Axel
dc.contributor.authorSandvig, Ioanna
dc.date.accessioned2021-04-19T07:41:02Z
dc.date.available2021-04-19T07:41:02Z
dc.date.created2020-08-23T20:49:10Z
dc.date.issued2020
dc.identifier.citationFrontiers in Aging Neuroscience. 2020, 12 (272), 1-29.en_US
dc.identifier.issn1663-4365
dc.identifier.urihttps://hdl.handle.net/11250/2738238
dc.description.abstractAlzheimer’s disease (AD) is a debilitating neurodegenerative disease characterized by the accumulation of two proteins in fibrillar form: amyloid-β (Aβ) and tau. Despite decades of intensive research, we cannot yet pinpoint the exact cause of the disease or unequivocally determine the exact mechanism(s) underlying its progression. This confounds early diagnosis and treatment of the disease. Cerebrospinal fluid (CSF) biomarkers, which can reveal ongoing biochemical changes in the brain, can help monitor developing AD pathology prior to clinical diagnosis. Here we review preclinical and clinical investigations of commonly used biomarkers in animals and patients with AD, which can bridge translation from model systems into the clinic. The core AD biomarkers have been found to translate well across species, whereas biomarkers of neuroinflammation translate to a lesser extent. Nevertheless, there is no absolute equivalence between biomarkers in human AD patients and those examined in preclinical models in terms of revealing key pathological hallmarks of the disease. In this review, we provide an overview of current but also novel AD biomarkers and how they relate to key constituents of the pathological cascade, highlighting confounding factors and pitfalls in interpretation, and also provide recommendations for standardized procedures during sample collection to enhance the translational validity of preclinical AD models.en_US
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleBridging the gap between fluid biomarkers for Alzheimer’s disease, model systems, and patientsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-29en_US
dc.source.volume12en_US
dc.source.journalFrontiers in Aging Neuroscienceen_US
dc.source.issue272en_US
dc.identifier.doi10.3389/fnagi.2020.00272
dc.identifier.cristin1824680
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU: xen_US
dc.description.localcodeCopyright © 2020 Bjorkli, Sandvig and Sandvig. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal